MT Newswires Live10:33
China's National Medical Products Administration added Sichuan Biokin Pharmaceutical's (SHA:688506) biologic drug T-Bren or BL-M07D1, for injection to its breakthrough therapy designation list, according to a Shanghai bourse filing on Monday.
The drug is undergoing twenty domestic and overseas clinical trials as a treatment for various forms of breast cancer, as well as other forms of cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
